Current Oncology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Age-dependent increased odds of cardiovascular risk factors in cancer survivors: Canadian Longitudinal Study on Aging cohort..  27:e368-e376. 2020
• Canadian cohort expanded access program of nivolumab plus ipilimumab in advanced melanoma.  27:204-214. 2020
• Inflammatory markers as prognostic factors of recurrence in advanced stage squamous cell carcinoma of the head and neck.  27:135-141. 2020
• A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.  27:90-99. 2020
• Canadian consensus: A new systemic treatment algorithm for advanced EGFR-mutated NSCLC.  27:e146-e155. 2020
• Immuno-oncology—the new paradigm of lung cancer treatment.  27:S78-S86. 2020
• Organizational guidance for the care of patients with head-and-neck cancer in Ontario.  27:e115-e122. 2020
• Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum.  27:e34-e42. 2020
• Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.  27:e43-e52. 2020
• The evolving field of bone imaging in multiple myeloma: is it time to abandon skeletal surveys?.  27:10-11. 2020
• Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study.  27:e1-e8. 2020
• OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing.  26:e618-e623. 2019
• An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.  26:240-246. 2019
• Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.  26:e551-e557. 2019
• Lessons learned from a cancer knowledge translation grants program: results of an evaluation.  26:272-284. 2019
• Psychedelics for psychological and existential distress in palliative and cancer care.  26:225-226. 2019
• Resource use in the last three months of life by lung cancer patients in southern Ontario.  26:247-252. 2019
• Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis.  26:e328-e333. 2019
• Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.  26:e372-e384. 2019
• Renal cell carcinoma in the Canadian Indigenous population.  26:e367-e371. 2019
• Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small cell lung cancer: a systematic review.  26:e398-e404. 2019
• Establishing funding rates for colonoscopy and gastroscopy procedures in Ontario.  26:98-101. 2019
• Surgical attitudes toward preoperative breast magnetic resonance imaging in women with early-stage breast cancer.  26:e194-e201. 2019
• Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.  26:e81-e93. 2019
• Integrating primary care providers through the seasons of survivorship.  26:48-54. 2019
• A Little Help from My Friends: Social Support in Palliative Rehabilitation.  25:358-365. 2018
• Moving research into practice: summary report of the Ex/Cancer meeting on physical activity, exercise, and rehabilitation in oncology.  25:E615-E621. 2018
• Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.  25:384-392. 2018
• Survival of Patients with Subglottic Squamous Cell Carcinoma.  25:e569-e575. 2018
• Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.  25:e576-e584. 2018
• Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.  25:e461-e474. 2018
• Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.  25:317-328. 2018
• Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.  25:300-306. 2018
• Is there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts.  25:e444-e453. 2018
• Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer.  25:1-9. 2018
• Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.  25:329-337. 2018
• Engaging cancer patients in clinical practice guideline development: a pilot study.  25:250-256. 2018
• Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic.  25:220-220. 2018
• Antiangiogenic therapies in non-small-cell lung cancer.  25:45-45. 2018
• Clinical practice guidelines in breast cancer.  25:151-151. 2018
• Comprehensive metastatic lung cancer care must include palliative care.  25:192-192. 2018
• Connecting people with cancer to physical activity and exercise programs: a pathway to create accessibility and engagement.  25:149-149. 2018
• Standardizing biomarker testing for Canadian patients with advanced lung cancer.  25:73-73. 2018
• Feasibility of assessing patient health benefits and incurred costs resulting from early dysphagia intervention during and immediately after chemoradiotherapy for head-and-neck cancer.  24:466-466. 2017
• Identifying barriers to accrual in radiation oncology randomized trials.  24:524-524. 2017
• Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.  24:540-540. 2017
• Staging and surgical approaches in gastric cancer: a clinical practice guideline.  24:324-324. 2017
• Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.  24:249-249. 2017
• Palliative care as a public health issue: understanding disparities in access to palliative care for the homeless population living in Toronto, based on a policy analysis.  24:187-187. 2017
• Quality of life for patients surviving cancer: are we moving ahead?.  24:151-151. 2017
• Challenges and insights in implementing coordinated care between oncology and primary care providers: a Canadian perspective.  24:120-120. 2017
• Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery.  24:146-146. 2017
• Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.  24:103-103. 2017
• Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.  24:111-111. 2017
• Multigene expression profile testing in breast cancer: is there a role for family physicians?.  24:95-95. 2017
• Systemic therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care Ontario clinical practice Guideline.  24:157-157. 2017
• Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists.  24:138-138. 2017
• A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.  24:33-33. 2017
• Does adjuvant radiation therapy benefit women with small mammography-detected breast cancers?.  24:28-28. 2017
• Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario.  24:50-50. 2017
• Guideline for radiotherapy with curative intent in patients with early stage, medically inoperable, non-small cell lung cancer.  24:44-44. 2017
• Introducing Dr. Matthew Seftel.  24:7-7. 2017
• Moving guidelines into action: a report from Cancer Care Ontario’s event Let’s Get Moving: Exercise and Rehabilitation for Cancer Patients.  24:65-65. 2017
• Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline.  23:418-418. 2016
• Early palliative care: taking ownership and creating the conditions.  23:367-367. 2016
• Clinical surveillance compared with clinical and magnetic resonance imaging surveillance for brain metastasis: a feasibility survey.  23:356-356. 2016
• Follow-up care for survivors of lymphoma who have received curative-intent treatment.  23:499-499. 2016
• Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.  23:343-343. 2016
• Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline.  23:280-280. 2016
• Fee-for-service cancer rehabilitation programs improve health-related quality of life.  23:233-233. 2016
• Approach to biomarker testing: perspectives from various specialties.  23:178-178. 2016
• Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.  23:276-276. 2016
• Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.  23:196-196. 2016
• Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.  23:179-179. 2016
• Management of small-cell lung cancer with radiotherapy—a pan-Canadian survey of radiation oncologists.  23:184-184. 2016
• Accrual of adolescents and young adults with cancer to clinical trials.  23:81-81. 2016
• Collaborative case conferences in rectal cancer: case series in a tertiary care centre.  23:138-138. 2016
• Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.  23:109-109. 2016
• Cost trajectories for cancer patients.  23:64-64. 2016
• Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.  23:52-52. 2016
• Temporal association between home nursing and hospital costs at end of life in three provinces.  23:42-42. 2016
• Worth his weight in….  22:372-372. 2015
• Are patients receiving the right care in the right place at the right time?.  22:315-315. 2015
• Quality of end-of-life cancer care in Canada: a retrospective four-province study using administrative health care data.  22:341-341. 2015
• Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?.  22:272-272. 2015
• The optimal organization of gynecologic oncology services: a systematic review.  22:282-282. 2015
• The organization of colposcopy services in Ontario: recommended framework.  22:287-287. 2015
• Views of family physicians about survivorship care plans to provide breast cancer follow-up care: exploration of results from a randomized controlled trial.  22:252-252. 2015
• Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline.  22:211-211. 2015
• Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review.  22:183-183. 2015
• Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5–6, 2014.  22:113-113. 2015
• Erratum: Tumour inflammatory response: adding fuel to the fire?.  22:133-133. 2015
• Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.  22:100-100. 2015
• Secular trends in the survival of patients with laryngeal carcinoma, 1995–2007.  22:85-85. 2015
• A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond.  22:43-43. 2015
• Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.  22:54-54. 2015
• Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.  22:49-49. 2015
• Safe handling of cytotoxics: guideline recommendations..  22:e27-e37. 2015
• Tumour inflammatory response: adding fuel to the fire?.  22:7-7. 2015
• A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.  21:234-234. 2014
• A systematic review of active treatment options in patients with desmoid tumours.  21:613-613. 2014
• Bortezomib in multiple myeloma: systematic review and clinical considerations.  21:573-573. 2014
• Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor.  21:564-564. 2014
• Treatment and follow-up strategies in desmoid tumours: a practice guideline.  21:642-642. 2014
• Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.  21:426-426. 2014
• Metastatic renal cell carcinoma without evidence of a primary renal tumour.  21:521-521. 2014
• Utilization of stereotactic ablative radiotherapy in the management of oligometastatic disease.  21:115-115. 2014
• Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome–positive or BCR-ABL–positive acute lymphoblastic leukemia: a Canadian consensus.  21:265-265. 2014
• Patients’ perceptions of gene expression profiling in breast cancer treatment decisions.  21:203-203. 2014
• Practice and documentation of palliative sedation: a quality improvement initiative.  21:100-100. 2014
• Rasch analysis of the Edmonton Symptom Assessment System and research implications.  21:186-186. 2014
• A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.  21:35-35. 2014
• Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.  21:96-96. 2014
• Oncology education in Canadian undergraduate and postgraduate medical programs: a survey of educators and learners.  21:75-75. 2014
• Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.  21:44-44. 2014
• A prospective evaluation of an interdisciplinary nutrition–rehabilitation program for patients with advanced cancer.  20:310-310. 2013
• An interprofessional palliative care oncology rehabilitation program: effects on function and predictors of program completion.  20:301-301. 2013
• Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.  20:539-539. 2013
• The association between malnutrition and psychological distress in patients with advanced head-and-neck cancer.  20:554-554. 2013
• Canadian integrative oncology research priorities: results of a consensus-building process.  20:289-289. 2013
• Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.  20:300-300. 2013
• Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline.  20:247-247. 2013
• A comparison of patient knowledge of clinical trials and trialist priorities.  20:193-193. 2013
• Liver resection for colorectal cancer metastases.  20:255-255. 2013
• Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.  20:223-223. 2013
• The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care..  20:e57-e58. 2013
• Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario.  20:e21-e33. 2013
• Consensus recommendations for cancer rehabilitation: research and education priorities.  20:64-69. 2013
• Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.  20:48-61. 2013
• Response to: What is the optimal management of dysphagia in metastatic esophageal cancer?.  19. 2012
• Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.  19:e422-e427. 2012
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.  19:259-268. 2012
• Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma.  19:e270-e279. 2012
• Management of a suspicious adnexal mass: a clinical practice guideline.  19:e244-e257. 2012
• Casting stones and casting aspersions: let’s not lose sight of the main issues in the euthanasia debate.  19:139-142. 2012
• Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study.  19:e129-e135. 2012
• Fertility risk discussions in young patients diagnosed with colorectal cancer.  19:155-159. 2012
• The importance of multidisciplinary team management of patients with non-small-cell lung cancer.  19:S7-S15. 2012
• Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the fourth annual meeting of the Canadian Consortium for Locally Advanced Breast Cancer.  19:106-114. 2012
• What is the optimal management of dysphagia in metastatic esophageal cancer?.  19. 2012
• A call for action in survivorship research and care.  19:16-20. 2012
• Challenges in knowledge translation: the early years of Cancer Care Ontario’s Program in Evidence-Based Care.  19:27-35. 2012
• Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review.  19:e16-e27. 2012
• Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis.  19:e9-e15. 2012
• Phenytoin toxicity in a patient receiving 5-fluorouracil–based chemotherapy for metastatic colorectal cancer.  18:264-265. 2011
• Survivorship services for adult cancer populations: a pan-Canadian guideline.  18:e265-e281. 2011
• Establishing a multicentre clinical research network: lessons learned.  18:e243-e249. 2011
• Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma..  18 Suppl 2:S11-S19. 2011
• Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer..  18 Suppl 2:S5-S10. 2011
• CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure.  18:e185-e190. 2011
• Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.  18:e180-e184. 2011
• Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy—systematic review and recommendations for clinical practice.  18:e191-e201. 2011
• Improving cancer control in Canada one case at a time: the “Knowledge Translation in Cancer” casebook.  18:76-83. 2011
• Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls.  18:e38-e45. 2011
• Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21.  18:84-90. 2011
• A comparative analysis of monthly out-of-pocket costs for patients with breast cancer as compared with other common cancers in Ontario, Canada.  18:e1-e8. 2011
• Terry Fox's legacy: a case for translational research.  17:262-263. 2010
• Cancer nutrition rehabilitation program: the role of social work.  17:12-17. 2010
• Terry Fox’s legacy: a case for translational research.  17:2-3. 2010
• Current management of castrate-resistant prostate cancer.  17:S72-S79. 2010
• Optimizing the management of HER2-positive early breast cancer: the clinical reality.  17:154-167. 2010
• Optimizing the management of HER2-positive early breast cancer: the clinical reality.  17:20-33. 2010
• Follow-up for women after treatment for cervical cancer.  17:65-69. 2010
• Estimating the national wage loss from cancer in Canada.  17:40-49. 2010
• Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study.  17:69-74. 2010
• Current management of castrate-resistant prostate cancer.  17. 2010
• Cancer diagnostic assessment programs: standards for the organization of care in Ontario.  16:29-41. 2009
• Clinician-patient communication: evidence-based recommendations to guide practice in cancer.  16:398-405. 2009
• Clinician-patient communication: evidence-based recommendations to guide practice in cancer.  16:42-49. 2009
• Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer.  16:13-20. 2009
• ¹³¹I-tositumomab in lymphoma.  16:32-47. 2009
• I-Tositumomab in lymphoma..  16:32-47. 2009
• The Role of Neoadjuvant HER2-Targeted Therapies in HER2 Overexpressing Breast Cancers.  16:48-57. 2009
• The Role of HER2-targeted Therapies in Women with HER2-Overexpressing Metastatic Breast Cancer.  16:25-35. 2009
• The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.  16:235-245. 2009
• Novel developments in angiogenesis cancer therapy.  16:191-195. 2009
• Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma..  16 Suppl 1:S60-S66. 2009
• Hormone replacement therapy and outcome for women with non-small cell lung cancer: can an association be confirmed?.  16:21-25. 2009
• Novel developments in angiogenesis cancer therapy.  16:50-54. 2009
• Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents.  16:S40-S44. 2009
• A Framework for the Organization and Delivery of Systemic Treatment.  16:4-15. 2009
• Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.  16:S62-S68. 2009
• I-131-Tositumomab in lymphoma.  16:32-47. 2009
• Inhibition of mTOR in kidney cancer.  16:S35-S41. 2009
• The role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic and Recurrent Non-Small Cell Lung Cancer: A Canadian National Consensus Statement.  16:27-48. 2009
• Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel.  15:44-47. 2008
• Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel..  15:298-301. 2008
• The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21).  15:279-285. 2008
• The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group.  15:8-16. 2008
• The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group.  15:262-270. 2008
• Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group.  15:179-184. 2008
• Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group.  15:14-19. 2008
• Editorial: Integrative Oncology and an Integrative Cancer Journal.  15:166-167. 2008
• Healing and Survivorship: What Makes a Difference?.  15:185-187. 2008
• Healing and survivorship: What makes a difference?.  15:20-22. 2008
• How do we evaluate outcome in an integrative oncology program?.  15:s78-s82. 2008
• Integrative Oncology: A Canadian and International Perspective.  15:s71-s73. 2008
• RESEARCH AND REGULATORY ISSUES FOR INTEGRATIVE ONCOLOGY.  15:s107.es53-s108.es63.. 2008
• Cancer Nutrition and Rehabilitation – Its Time has Come!.  15:117-122. 2008
• Chinese Medicine and Biomodulation in Cancer Patients (Part One).  15:42-48. 2008
• Chinese Medicine and Biomodulation in Cancer Patients (Part Two).  15:8-30. 2008
• Research and regulatory issues for integrative oncology.  15:S53-S63. 2008
• Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer.  14:195-208. 2007
• Treatment of Depression in Cancer Patients.  14:180-188. 2007
• Phase II Testing of Sunitinib: The NCIC CTG IND Program Trials IND.182 - 185.  14:154-161. 2007
• Alemtuzumab in Chronic Lymphocytic Leukemia: A Systematic Review and Clinical Practice Guideline.  14:96-109. 2007
• A Tale of Two Time Periods: Ovarian Cancer Trends in Ontario.  14:57-60. 2007
• Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The NCIC CTG MY.11 Trial.  14:61-65. 2007
• Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind.  14:45-56. 2007
• Radiofrequency Ablation and Cryoablation of Renal Tumours.  14:34-38. 2007
• Cross-border referral for early breast cancer: an analysis of radiation fractionation patterns..  13:124-129. 2006
• Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review..  13:81-93. 2006
• Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2..  13:99-107. 2006
• Promoting best gynecologic oncology practice: a role for the Society of Gynecologic Oncologists of Canada..  13:94-98. 2006
• Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1..  13:14-26. 2006
• Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma.  12:3-17. 2005
• Psychological, physical, social and economic impact of traveling great distances for cancer treatment.  12:1-7. 2005
• Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.  11:41-52. 2004
• Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns.  11:68-71. 2004
• Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer.  10:146-160. 2003
• Role of octreodite in the management of patients with cancer.  10:161-179. 2003
• Role of taxanes in the management of metastatic breast cancer.  10:68-83. 2003
• Use of gemcitabine in non-small-cell lung cancer.  10:3-26. 2003
• Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines.  9:7-12. 2002
• The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer.  8:50-59. 2001
• Use of irinotecan combined with 5-fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer.  8:60-68. 2001
• Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.  8:16-27. 2001
• Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.  8:6-15. 2001
• Treatment of locally advanced squamous cell carcinoma of the head and neck: A summary and overview.  8:3-5. 2001
• Drug therapy for chronic myeloid leukaemia.  7:229-241. 2000
• Participation patterns of oncologists in the development of clinical practice guidelines.  7:252-257. 2000
• The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary.  7:242-251. 2000
• Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer.  7:149-161. 2000
• Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients.  7:136-148. 2000
• Use of capecitabine in stage IV breast cancer: An evidence summary.  7:84-90. 2000
• Use of irinotecan in secondline treatment of metastatic colorectal carcinoma.  7:29-36. 2000
• 'Two solitudes' or 'A mouse in bed with two elephants'.  7:3-4. 2000
• Use of vinorelbine in stage IV breast cancer: An evidence summary.  7:24-28. 2000
• Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer.  7:98-109. 2000
• Optimum radiation fractionation for T1 N0 glottic carcinoma.  7:91-97. 2000
• The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer.  7:162-172. 2000
• Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab.  6:131-137. 1999
• Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients.  6:155-160. 1999
• Use of biphosphonates in patients with bone metastases from breast cancer.  6:144-154. 1999
• Use of rituximab in the treatment of lymphoma: An evidence summary.  6:228-235. 1999
• The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia.  6:90-102. 1999
• Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies.  6:74-77. 1999
• The role of adjuvant systemic therapy in node-negative breast cancer.  6:78-89. 1999
• Predictors of intention to act: High-school students and cervical screening.  6:36-42. 1999
• New initiatives in the management of recurrent breast cancer.  5:188-194. 1998
• Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies.  5:181-187. 1998
• Bone metastases: A review of their pathogenesis.  5:114-118. 1998
• Recent reports in breast cancer.  5:143-147. 1998
• High-grade glioma management and response assessment—recent advances and current challenges.  23:383-383.
• Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? 2009
• The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2009
• The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2008
• 22nd Annual San Antonio Breast Cancer Symposium, December 8-11, 1999 1999
• 35th Annual Meeting of the American Society of Clinical Oncology: What's new in breast cancer 1999
• 21st Annual San Antonio Breast Cancer Symposium, December 12-15, 1998 1999
• 20th annual San Antonio Breast Cancer Symposium, December 3-6, 1997 1998
• International St. Gallen conference: Adjuvant therapy of primary breast cancer, February 25-28, 1998 1998

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Oncology & Carcinogenesis (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 1198-0052

Electronic International Standard Serial Number (EISSN)

• 1198-0052
• 1718-7729